Risk factors

Risk section changes are minimal, limited to minor wording refinements in financial statement estimation risks.

Aircraft asset obsolescence and motor vehicle regulatory compliance risks were newly added. Contract cancellation risks and key executive roles changed. Material shortages and hydraulic fracturing asset sales were updated.

Government contracts generate over 90% of revenue, making procurement, renewals, pricing, and public-sector decisions central risks.

Government-contract risk now emphasizes budget cycles, shutdowns, bidding, administrations, spending cuts, and complex procurement requirements.

Debt and structured-finance risks receive greater emphasis, including CLOs, noteholder protections, refinancing liquidity and incentive-fee conflicts.

Acorn Energy faces new international supply chain and tariff risks from sourcing components in China, Taiwan, and Mexico. Cash increased to $4,454,000 while customer concentration dropped to 42%. Share counts, option prices, and unvested options shifted.

Adial Pharmaceuticals highlights new collaboration risks with Molteni for AD04, healthcare price-control regulations, and federal shutdown impacts.

A.K.A. Brands updated its risk disclosures regarding sales tax compliance, geographic expansion plans, and stock split details.

Aligos highlights going concern doubts with cash runway only through the third quarter of 2026. International operations face escalating tariff threats, supply chain complexities, and foreign regulatory hurdles. Intellectual property and licensing dependencies remain critical, notably a $9.0 million payment made to Emory University.

The company added a specific risk regarding acquisition strategies and integration challenges. Cost structure competition was merged into internal control disclosures.

New regulatory pressures around the GENIUS Act and debanking rules heighten compliance and fraud risks for Amalgamated Financial Corp. Pension contributions rose to $8.2 million in 2025 alongside evolving fraud and third-party vendor exposures.

aTyr Pharma faces new securities class action litigation and Nasdaq delisting risk as its stock traded below $1.00.